Warfarin remains one of the most widely used oral anticoagulants. As a vitamin K antagonist (VKA) with a narrow therapeutic index, it demands careful titration and vigilant monitoring. The newer oral anticoagulants (NOACs), such as dabigatran, apixaban, and rivaroxaban, are steadily displacing warfarin in many indications, but their cost remains prohibitive for a large proportion of patients. Moreover, in valvular atrial fibrillation and in patients with mechanical valve replacement, warfarin retains its place as the drug of choice; current guidelines do not yet support NOAC use in these settings.
Dosage adjustment of warfarin is a recurring clinical task on Medicine and Cardiology wards. The table below provides a structured reference for this purpose.
Identifying high-risk patients
Certain patient groups carry an elevated risk of bleeding on warfarin therapy. Several guidelines recommend the use of scoring systems, such as CHA2DS2-VASc, to weigh the benefit of anticoagulation against this risk in the following situations:
- Age above 60 years
- Malnourishment or low BMI
- Congestive heart failure
- Liver disease (Child-Pugh class B or C)
- Recent major surgery, or otherwise elevated bleeding risk
- Concurrent use of medications known to potentiate warfarin or increase bleeding risk, including amiodarone, atorvastatin, rosuvastatin, fluconazole, itraconazole, ketoconazole, voriconazole, sulfamethoxazole, aspirin above 100 mg/day, ciprofloxacin, levofloxacin, metronidazole, sulfasalazine, and disulfiram
A baseline INR should be obtained during the current admission before initiating therapy. Oral anticoagulation should overlap with subcutaneous heparin or low molecular weight heparin (LMWH) for a minimum of five days, and until the INR remains within the therapeutic range on two consecutive measurements. In newly initiated patients, INR should be monitored every 24 hours until the target range is achieved. Once stable, and provided there have been no recent medication changes, patients may be followed with INR checks every 30 to 60 days.
Warfarin and diet
As vitamin K directly antagonises warfarin’s action, patients should be advised to limit foods high in vitamin K to achieve a prompt and stable therapeutic INR. We also recommend administering the tablet in the evening, around 5 to 6 PM, with a food-free interval of one hour before and after, since warfarin’s bioavailability improves under fasting conditions.
Foods to avoid or limit while on warfarin include:
- Green leafy vegetables, such as spinach and lettuce
- Cruciferous vegetables, including spring onions, broccoli, cauliflower, and cabbage
- Green tea
Alcohol and cranberry juice should also be avoided, as both unpredictably potentiate warfarin’s anticoagulant effect.
MEDiscuss CDSS Tool
While this reference table has long served as a bedside aid for warfarin dosing, the CDSS Warfarin and Acitrom Titration tool now offers a more rigorous, patient-specific alternative for this task.
This tool calculates total weekly dose adjustments and day-by-day initiation nomograms for warfarin and acenocoumarol (Acitrom), keyed to indication and target INR, with built-in conversion between the two agents.
The tool works from total weekly dose rather than daily averages, sets the target INR automatically once the indication is selected (2.5 for most indications, 3.0 for a mechanical mitral valve), and flags the bridging decision for VTE and mechanical valves without requiring manual lookup. It also includes a dedicated pathway for the antitubercular interaction with rifampicin, which is a frequent but often under-addressed complication on Indian wards.
Did you like this? You may also be interested in our ICU charts.
